NCT06551506: The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
- State
- Completed
- Phase
- Phase 4
- People
- 181 taking part
- Started
- 19 Sep 2024
- Primary completion
- 5 May 2026
- Arms
- Group 2
- Results
- None posted
- 13 Aug 2024: Trial registered
- 19 Sep 2024: Trial started
- 5 May 2026: Trial completed